Ptc Therapeutics Stock Fundamentals
| PTCT Stock | USD 25.21 0.20 0.79% |
PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.
At this time, PTC Therapeutics' Total Operating Expenses is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 204.5 M in 2024, whereas EBITDA is likely to drop (118.5 M) in 2024. PTC | Select Account or Indicator |
PTC Therapeutics Company Return On Equity Analysis
PTC Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current PTC Therapeutics Return On Equity | -77.4 |
Most of PTC Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
PTC Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, PTC Therapeutics has a Return On Equity of -77.4012. This is 222.91% higher than that of the Biotechnology sector and 112.29% higher than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
PTC Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PTC Therapeutics's current stock value. Our valuation model uses many indicators to compare PTC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PTC Therapeutics competition to find correlations between indicators driving PTC Therapeutics's intrinsic value. More Info.PTC Therapeutics is rated below average in return on equity category among related companies. It is regarded fourth in return on asset category among related companies . At this time, PTC Therapeutics' Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value PTC Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PTC Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PTC Therapeutics' earnings, one of the primary drivers of an investment's value.PTC Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in return on equity category among related companies.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 4.0B | 2.8B | 2.7B | 2.1B | 1.3B | |
| Enterprise Value | 2.5B | 4.2B | 2.5B | 3.0B | 1.9B | 1.2B |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.34 B | ||||
| Shares Outstanding | 76.61 M | ||||
| Shares Owned By Insiders | 2.78 % | ||||
| Shares Owned By Institutions | 97.22 % | ||||
| Number Of Shares Shorted | 10.26 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 937.82 M | ||||
| Gross Profit | 2.63 M | ||||
| EBITDA | (112.81 M) | ||||
| Net Income | (626.6 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 415.03 M | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (10.81) X | ||||
| Cash Flow From Operations | (158.42 M) | ||||
| Short Ratio | 11.39 X | ||||
| Earnings Per Share | (8.37) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 27.91 | ||||
| Number Of Employees | 988 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 1.95 B | ||||
| Total Asset | 1.9 B | ||||
| Retained Earnings | (3.28 B) | ||||
| Working Capital | 615.53 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.9 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 801 K | 761 K | |
| Total Revenue | 937.8 M | 984.7 M | |
| Cost Of Revenue | 288.1 M | 302.5 M | |
| Stock Based Compensation To Revenue | 0.14 | 0.13 | |
| Sales General And Administrative To Revenue | 0.52 | 0.80 | |
| Research And Ddevelopement To Revenue | 0.71 | 0.68 | |
| Capex To Revenue | (0.13) | (0.14) | |
| Revenue Per Share | 12.53 | 13.16 | |
| Ebit Per Revenue | (0.37) | (0.39) |
PTC Therapeutics Investors Sentiment
The influence of PTC Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in PTC. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to PTC Therapeutics' public news can be used to forecast risks associated with an investment in PTC. The trend in average sentiment can be used to explain how an investor holding PTC can time the market purely based on public headlines and social activities around PTC Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
PTC Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for PTC Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average PTC Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on PTC Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PTC Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PTC Therapeutics' short interest history, or implied volatility extrapolated from PTC Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PTC Therapeutics Piotroski F Score and PTC Therapeutics Altman Z Score analysis. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.531 | Quarterly Revenue Growth 0.834 | Return On Assets (0.12) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.